To send a press release or to contact the editorial department, email firstname.lastname@example.org.
Simone Fishburn, Ph.D., Vice President & Editor in Chief
Simone serves as Vice President and Editor in Chief, bringing experience from both industry and academia in translational science, where she focused for over 15 years on the scientific, commercial and strategic considerations for advancing laboratory discoveries to products for patients.
Since joining BioCentury in 2013, Simone has written and edited on innovation from idea to patient, most recently serving as Executive Editor. Previously, she was a director of translational research at Nektar Therapeutics and a senior managing consultant at Exponent Inc., where she specialized in projects for the biopharma industry. Simone serves as an adviser on multiple university translational programs, including initiatives at the University of California and Stanford University. Simone is also active in programs to advance women's careers; she is a board member of Women In Bio and served as its President in 2013-14.
Simone is a Fulbright scholar and performed a post-doc at the University of California San Francisco. She holds a Ph.D. in Molecular Pharmacology from the Weizmann Institute of Science, and an M.A. and B.A. in Pharmacology from Cambridge University.
Jeff Cranmer, Executive Editor
Jeff directs and edits the short-form articles at BioCentury, including financial, corporate, regulatory and clinical items, Emerging Company Profiles and Translation in Brief.
Jeff leads the coverage of breaking news, coordinating the flow of global news from North America, Europe and Asia.
Jeff joined BioCentury as Editor of BioCentury Extra in 2005 and became Managing Editor of BioCentury in 2010. He became Executive Editor in 2017.
Prior to BioCentury, Jeff served on the editorial teams of MarketWatch, Institutional Investor and Asia Times. He is co-author of the first edition of the Rough Guide to Laos. Jeff has an A.B. from Princeton University in English and an M.A. from the Johns Hopkins School of Advanced International Studies.
Senior Editors & Bureau Heads
Selina Koch, Ph.D., Senior Editor
Selina directs and edits the long-form analytical articles and infographics at BioCentury, covering scientific, corporate and strategic content across the biomedical ecosystem. Selina has domain expertise across a wide range of topics relevant to drug developers. Her first love is neurology. She has a deep understanding of neurodegenerative disorders, particularly Alzheimer’s disease, as well as conditions affecting ion channels.
Selina joined BioCentury in 2014 after earning a Ph.D. in Neuroscience and conducting postdoctoral research at the University of California San Francisco. Her experiments investigated the role of synaptic plasticity in shaping the development of brain circuits. She holds a B.S. in Neurobiology and Behavior from the University of Washington.
Erin McCallister, Senior Editor & Head, Clinical Development & Market Access
Erin guides BioCentury's clinical development, market access and reimbursement coverage. She has written extensively on novel clinical trial designs and drug pricing strategies, as well as M&A, corporate strategy, and the competitive landscape across multiple therapeutic areas.
Prior to joining BioCentury in 2008, Erin served as a program officer for the Great Lakes Protection Fund and a biologist at Dow AgroSciences. She holds an M.Sc. in Environmental Science and Policy from the University of Chicago and a B.S. in Biology from Purdue University.
Steve Usdin, Senior Editor, Washington, & Head, Policy & Regulation
Steve has been BioCentury’s Washington Editor since 1993, covering political and policy issues affecting the life sciences sector. He also is BioCentury’s Senior Editor responsible for coverage of social issues involving biotechnology, as well as the former host of BioCentury This Week, BioCentury's public affairs television program broadcast in 2010-14.
Steve’s reporting about biotechnology and biomedical policy has been cited in The Economist, The Wall Street Journal, The Washington Post, New Scientist and other publications. In 2012, the FDA Alumni Association named Steve the Harvey W. Wiley Lecturer, making him the first journalist to receive the Wiley Award.
Steve is also a widely recognized scholar on espionage and the Cold War. He is the author of Bureau of Spies: The Secret Connections between Espionage and Journalism in Washington and Engineering Communism: How Two Americans Spied for Stalin and Founded the Soviet Silicon Valley.
Karen Tkach Tuzman, Ph.D., Associate Editor & Head, Discovery and Preclinical Research
As Head of Discovery and Preclinical Research, Karen guides BioCentury’s coverage of emerging biology and technologies. She has written extensively about immunology, synthetic biology and data science, covering innovative breakthroughs in industry and academia, and dissecting trends in company formation and investments around new science. She coordinates activities and interactions with BioCentury’s Scientific Advisory Board.
Karen joined BioCentury in 2015 after a postdoctoral research fellowship in Stanford University's Department of Chemical and Systems Biology. She holds a Ph.D. in Immunology from Weill Cornell Medicine and a B.A. in Molecular and Cell Biology from the University of California Berkeley.
Jonathan is News Editor, serving as BioCentury’s primary point of contact for companies’ and investors’ news. Prior to joining BioCentury in 2019, Jonathan worked as an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a B.A. from Tufts University and is earning an MPH with a focus on Health Policy from the CUNY Graduate School of Public Health & Health Policy.
Paul writes and edits stories on product development, company strategy and has a particular focus on venture financings and M&A. He is a frequent contributor to BioCentury’s financial column, where he provides synopses of trends in financing, insight into deals and analyses of the week’s market moves. Paul was the Editor of BioCentury Extra in 2014-17. He has written for a variety of publications about venture capital, biotech, information technology and music; among them are The Pink Sheet, Billboard, The Deal and GigaOm.
Stephen is BioCentury’s Associate Editor in the U.K., where he serves as one of the company’s primary points of contact with European companies and investors. Stephen has covered clinical development, corporate strategy and finance in Europe, the U.S. and China for BioCentury for over a decade and is a frequent contributor to BioCentury’s quarterly Financial Markets Preview and annual Buyside View and European Finance reports. He holds B.A.s in Biology and History from Bethel University and an M.Phil. in History from Oxford University.
Based in Boston, Val covers finance and M&A for BioCentury. Prior to joining the company in 2019, she spent nearly a decade at MarketWatch covering the biotechnology, pharmaceutical and medical device sectors. In addition to MarketWatch, Val’s work has been published by The Wall Street Journal, Dow Jones Newswires and Reuters. She has also provided business commentary for CBS Radio, Fox Business News, PBS and New England Cable News.
Virginia edits news and analysis stories for BioCentury and manages the Emerging Company series, which profiles the formation of innovative companies across the globe. Since joining BioCentury in 2014, Virginia has written and edited stories on M&A, product development and translational news and has been a frequent contributor to BioCentury’s quarterly Financial Markets Preview and annual Buyside View reports. She holds a B.A. in Biology from Cornell University.
Lauren has written on emerging technologies and therapeutics since joining BioCentury in 2007. As Associate Editor, she guides BioCentury’s coverage of CRISPR and has written extensively on cell and gene therapies, the microbiome and gene control, as well as IP issues affecting the industry. Lauren holds a B.S.E. in Bioengineering from the University of Pennsylvania and an MBA from Temple University.
With a background in molecular biology and cancer epigenetics, Inhua represents BioCentury in Continental Europe from her office near Maastricht, the Netherlands.
Prior to joining BioCentury in 2019, Inhua consulted for the Massachusetts Institute of Technology, the European Patients Academy for Therapeutics Innovation and the U.S.-based Sickle International Family Coalition; she also served as Life Science Lead at IT consultancy Appecon GmbH. She was an Assistant Professor of Applied Sciences at Zuyd University and did a postdoc at the Netherlands Cancer Institute.
Inhua holds a Ph.D. in Molecular Biology from the Open University in collaboration with the University of Heidelberg, and a B.S. from Cornell University. She sits on the board of Unalone, a Swiss non-profit organization dedicated to patient empowerment.
Meredith Durkin Wolfe, Associate Editor, Data & Analytics
Meredith leads research analytics for BioCentury's editorial team, responsible for generating and analyzing the data that informs BioCentury's stories and accompanying charts and tables. Since joining BioCentury in 2008, her research has supported BioCentury's quarterly Financial Markets Preview and annual Buyside View and European Finance reports, as well as analysis articles on M&A, molecular targets and new modalities. Prior to BioCentury she worked in circadian rhythms research at Rush University and in market research with clients from a variety of industries. Meredith has an A.B. in Anthropology from the University of Chicago.
Allison Johnson, Ph.D.
Since joining BioCentury in 2017, Allison has written extensively on innovations in drug development, including next-generation gene therapy, antibody-drug conjugates, allosteric modulation and single cell analysis. She received her Ph.D. in Molecular and Cellular Pathology from the University of Michigan, where she studied blood-brain barrier permeability. She holds a B.S. in biochemistry from Juniata College.
Winnie Pong, Ph.D.
Winnie writes data-driven stories and supports the data analysis and visualization efforts of BioCentury’s editorial team. Before joining BioCentury in 2016, Winnie was a medical writer at DynaMed and a postdoctoral fellow studying cancer neuroimmunology at Washington University Medical School in St Louis. She holds a Ph.D. in Neurobiology from Boston University and a B.S. in Biochemistry from the University of Massachusetts Amherst.
Elizabeth writes news and analysis briefs with a focus on company formation, venture financings, deals and legal proceedings involving industry. Before joining BioCentury in 2017, Elizabeth covered immunology, microbiology and ecology at Science News magazine in Washington, D.C. She earned a B.A. in Journalism from the University of Arizona, where she was a NASA Space Grant intern.
Hongjiang Li, Ph.D.
Hongjiang covers news on capital markets, policy and regulatory developments with a focus on China, writes on emerging companies and is a principal contributor and editor of BioCentury’s Distillery section. Before joining BioCentury in 2016, Hongjiang was a research scientist at the Institute of Science and Technology in Austria, Ghent University and the University of California Riverside. She holds a Ph.D. in Biotechnology from Peking University, a PPM in Bioscience Management from Keck Graduate Institute and a B.S. in Biotechnology from Sichuan University.
Claire covers translational science for BioCentury’s Distillery section. Since joining BioCentury in 2013, she has covered breaking news on venture financings, clinical development and M&A as a Staff Writer and has served as BioCentury’s Fact Checker and Copy Editor. She is pursuing an M.D. from the University of Nevada Reno and holds a B.S. in Biochemistry from the University of Chicago.
Sandi Wong, Ph.D.
Sandi manages BioCentury’s Distillery section, which features academic discoveries with commercial potential. Sandi also contributes news briefs on drug discovery and development, venture financings and M&A, and has written extensively about emerging companies, infectious diseases and therapies targeting the gut-brain axis. Prior to joining BioCentury in 2018, Sandi was a scientist at precision antimicrobial company Locus Biosciences Inc. and conducted postdoctoral research on the neonatal microbiome at Duke University. She holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill and a B.A. in Molecular and Cell Biology from the University of California Berkeley.